Rhythm Biosciences Confirms RHYO Options Deadline and Underwriting Terms

Rhythm Biosciences Ltd. ( (AU:RHY) ) has provided an announcement.

Rhythm Biosciences has confirmed that the deadline for exercising its RHYO options is 5:00 pm Melbourne time on 31 March 2026 and reports that a significant volume of options has already been exercised. The company’s underwriting agreement with CPS Capital Group remains in place, and Rhythm expects to issue the shortfall notice to the underwriter on 2 April 2026, reinforcing funding support for the commercialisation and growth of its ColoSTAT and geneType cancer diagnostic products.

The clarification that the prospectus termination provisions accurately reflect the executed underwriting agreement, superseding earlier terms flagged in February 2026, provides greater certainty around the capital-raising structure. This stability underpins Rhythm’s efforts to expand its novel diagnostic offerings in colorectal cancer detection and multi-disease genetic risk assessment, which could strengthen its competitive position in the cancer diagnostics and preventive healthcare sectors.

The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.

More about Rhythm Biosciences Ltd.

Rhythm Biosciences Ltd is an Australian medical diagnostics company focused on developing simple, affordable blood tests for the accurate and early detection of cancers. Founded in 2017 and headquartered in Melbourne, the company is commercialising its ColoSTAT colorectal cancer blood test and the geneType genetic risk assessment platform, targeting global preventive healthcare and precision medicine markets.

Average Trading Volume: 946,976

Technical Sentiment Signal: Buy

Current Market Cap: A$63.51M

Learn more about RHY stock on TipRanks’ Stock Analysis page.